Artelo Biosciences shares surge as company pitches GLP-1 companion-therapy angle for ART27.13

By: Quiver PriceTracker

Posted: 3 hours ago / March 27, 2026 9:23 p.m. UTC

ARTL

Artelo Biosciences, Inc. (ARTL) is up 170.5% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to a newly disclosed strategic expansion for lead candidate ART27.13 as a potential companion therapy for GLP-1 drugs, focused on preserving muscle mass during weight loss. Given ARTL’s micro-cap profile and recent reverse split, the stock can also see outsized swings on news flow and positioning.

Details:

The company announced it is expanding ART27.13 development toward muscle preservation for patients using GLP-1 receptor agonists, citing preclinical study initiation, a provisional patent filing, and publication of independent research supporting the program.

In the same disclosure, management referenced prior CAReS observations (lean body mass/physical activity measures) as part of the rationale for exploring the GLP-1 companion-therapy concept.

An 8-K also described a $315,000 10% promissory note financing with a conversion feature tied to a discount to recent bid prices, which can add to volatility in thinly traded micro-caps.

Separately, Nasdaq previously set a March 30, 2026 deadline for the company to regain compliance with the minimum stockholders’ equity requirement, which may be contributing to speculative trading behavior into that date.

Sources:

SEC (EDGAR), Artelo Biosciences Investor Relations, TradingView

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ARTL Hedge Fund Activity

We have seen 8 institutional investors add shares of $ARTL stock to their portfolio, and 6 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS GROUP AG added 33,412 shares (+15986.6%) to their portfolio in Q4 2025, for an estimated $40,762
TWO SIGMA INVESTMENTS, LP added 20,669 shares (+inf%) to their portfolio in Q4 2025, for an estimated $25,216
DRW SECURITIES, LLC removed 17,185 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $20,965
VIRTU FINANCIAL LLC added 16,865 shares (+inf%) to their portfolio in Q4 2025, for an estimated $20,575
GEODE CAPITAL MANAGEMENT, LLC added 11,398 shares (+inf%) to their portfolio in Q4 2025, for an estimated $13,905
TOWER RESEARCH CAPITAL LLC (TRC) added 1,903 shares (+inf%) to their portfolio in Q4 2025, for an estimated $2,321
MORGAN STANLEY removed 1,100 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $1,342

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.